skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

The T47D/TR-1 is a breast cancer cell line resistant to tamoxifen. The T47D/TR-1 cell line has been established by long term treatment of T47D/S2 cells with 1 µM tamoxifen. Clonal selection was performed in medium without tamoxifen. After growth in presence of 1 µM tamoxifen for 10 months, the growth rate was similar to the parental cells.T47D/TR-1 cells are ER alpha positive & express progesterone receptor, but at reduced level compared to parental T7D/S2 cells. T47D/TR-1 cells are growth inhibited by fulvestrant. Oestrogen receptor.

General Info



Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.



T47D/TR-1 cells are ER alpha positive & express progesterone receptor, but at reduced level compared to parental T7D/S2 cells. T47D/TR-1 cells are growth inhibited by fulvestrant. Oestrogen receptor.

Tissue of Origin



Adherent polygonal epithelia

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11,13
D3S1358: 15,17
D5S818: 12
D7S820: 11
D8S1179: 13
D13S317: 12
D16S539: 10
D18S51: 17
D21S11: 28,31
FGA: 23
TH01: 6
TPOX: 11
Penta D: 10,12
Penta E: 7,14
vWA: 14


Anti-oestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for anti-oestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth. T47D/TR-1 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells. T47D/TR-1 are growth inhibited by fulvestrant



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C. Recommend media changes every 2-3 days.

Culture Medium

Phenol red-free RPMI 1640 + 2% FCS + Glutamax + 8µg Insulin/ml + 1 µM tamoxifen.

Growth Mode


Additional Info


Cancer Research Technologies Limited (Ximbio)

Country of Origin


Hazard Group (ACDP)

Hazard Group (ACDP) 2



Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943. Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472. Thrane et al. 2015 Oncogene. Aug 6;34 (32):4199-210. doi: 10.1038/onc.2014.351. Epub 2014 Nov 3. Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: T47D/TR-1 (ECACC 16022513).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.